Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ: MRNA) or Pfizer Inc (NYSE:PFE), and BioNTech SE (NASDAQ:BNTX) COVID-19 vaccines for older people and certain immunocompromised individuals. 

The agency said the new boosters would be administered at least four months after the previous dose.

 The FDA also authorized the second booster dose of the vaccines for younger people with compromised immune systems - those aged 12 and older for the Pfizer/BioNTech shot and 18 and older for Moderna's.

The authorization comes as some scientists have raised concerns about the highly contagious and newly predominant BA.2 omicron subvariant, which has driven new spikes in COVID-19 cases in other countries.

Related: Pfizer, Moderna, and J&J Face Shareholder Pressure To Make COVID-19 Shots More Available To Poorer Countries: WSJ.

"Based on an analysis of emerging data, a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine could help increase protection levels for these higher-risk individuals," top FDA official Dr. Peter Marks said in a statement.

The FDA said it had looked at data from a relatively small, ongoing clinical trial in Israel to help make its decision. In addition, safety data from more than 700,000 people who received second boosters in Israel revealed no new concerns, the agency said.

Price Action: PFE shares are down 0.71% at $52.90, BNTX stock is up 3.33% at $171.86, and MRNA 2.81% at $177.94 during the market session on the last check Tuesday.

Image by Spencer Davis from Pixabay

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.